In the liver and adipose tissue, preclinical studies have shown that URAT1 inhibition ameliorates steatosis, insulin resistance, and mitochondrial dysfunction largely through reductions in oxidative stress, lipogenesis, and pro-inflammatory signaling [11]. Here, SLC22A12 is linked to Insulin resistance.